Fig. 5

Inhibition of REV7 overcomes resistance to 5-FU and oxaliplatin in vitro. a Relative cell viability to 5-Fu in HT29 5-Fu-R, HT29 5-Fu-R-KO1, HT29 5-Fu-R-KO2, HT29 5-Fu-R-KO1 + REV7 and HT29 5-Fu-R-KO2 + REV7 cell lines. Cells were treated with 0 µM, 1 µM, 2 µM, 4 µM, 8 µM of 5-Fu for 48 h. The statistical analysis of cell viability was calculated by using one-way ANOVA. Variation is indicated and presented as mean ± SEM. b Relative cell viability to oxaliplatin in HT29 Oxa-R, HT29 Oxa-R-KO1, HT29 Oxa-R-KO2, HT29 Oxa-R-KO1 + REV7 and HT29 Oxa-R-KO2 + REV7 cell lines. Cells were treated with 0 µM, 5 µM, 10 µM, 20 µM, 40 µM of oxaliplatin for 48 h. The statistical analysis of cell viability was calculated by using one-way ANOVA. Variation is indicated and presented as mean ± SEM. c 5-Fu (1 µM) induced relative caspase 3/7 activity in cells analyzed in Fig. 4a. d Oxaliplatin (10 µM) induced relative caspase 3/7 activity in cells analyzed in Fig. 4b. *p < 0.05; ***p < 0.001. The p-values were calculated by using by one-way ANOVA. Variation is indicated and presented as mean ± SEM